pubmed-article:7751891 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0006644 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C1516238 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0549379 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0054427 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0055987 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0075860 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
pubmed-article:7751891 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
pubmed-article:7751891 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:7751891 | pubmed:dateCreated | 1995-6-22 | lld:pubmed |
pubmed-article:7751891 | pubmed:abstractText | We sought to compare three doxorubicin-based therapies for metastatic breast cancer for response frequency, time to treatment failure (TTF), and survival. | lld:pubmed |
pubmed-article:7751891 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:language | eng | lld:pubmed |
pubmed-article:7751891 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7751891 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:7751891 | pubmed:month | Jun | lld:pubmed |
pubmed-article:7751891 | pubmed:issn | 0732-183X | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:HollandJJ | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:PerryMM | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:AisnerJJ | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:AbramsJJ | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:PerloffMM | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:PanasciLL | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:BudmanDD | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:CirrincioneCC | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:CitronMM | lld:pubmed |
pubmed-article:7751891 | pubmed:author | pubmed-author:MussHH | lld:pubmed |
pubmed-article:7751891 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:7751891 | pubmed:volume | 13 | lld:pubmed |
pubmed-article:7751891 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:7751891 | pubmed:authorsComplete | N | lld:pubmed |
pubmed-article:7751891 | pubmed:pagination | 1443-52 | lld:pubmed |
pubmed-article:7751891 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:meshHeading | pubmed-meshheading:7751891-... | lld:pubmed |
pubmed-article:7751891 | pubmed:year | 1995 | lld:pubmed |
pubmed-article:7751891 | pubmed:articleTitle | Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. | lld:pubmed |
pubmed-article:7751891 | pubmed:affiliation | University of Maryland Cancer Center, Baltimore, USA. | lld:pubmed |
pubmed-article:7751891 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:7751891 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:7751891 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:7751891 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:7751891 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:7751891 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7751891 | lld:pubmed |